The Mary -Yoshio Translational Hexagon (MYTH), the translational division of Nichi-In Centre for Regenerative Medicine (NCRM) has been pursuing several projects on cell based therapies. The important ones are in Vision and Cancer.
In ophthalmology, our focus has been (i) Regenerating the Corneal Epithelium using patients own Limbal Tissue-Derived Stem Cells and (ii) Repairing the damaged Corneal Endothelium using Nanomaterial based transplantation of Corneal Endothelial Precursors.
For cancer, we provide NK cells and T cells based Autologous Immune Enhancement Therapy (AIET) which has been in clinical practice in Japan since 90s. We have been working on various methodologies to further enhance the outcome of this autologous immune cell based cancer therapies to both prevent and treat cancer.